Diagnostic companies AnchorDx and DiaCarta have announced a long-term collaboration for the development of new cancer screening tests.

The companies will work together for the global development and commercialisation of these molecular diagnostic products.

The partnership will utilise technologies for DNA methylation and mutation detection developed by each company. 

In July 2021, AnchorDx received breakthrough device designation from the US Food and Drug Administration (FDA) for the DNA methylation test.

AnchorDx is also presently carrying out a prospective and registrational clinical study for the UriFind PMA application, with DiaCarta participating as one of the clinical testing laboratories.

DiaCarta CEO and president Dr Adam (Aiguo) Zhang said: “Partnering with AnchorDx allows both companies to combine their technical expertise to develop high-precision mutation and methylation assays with the needed high sensitivity and specificity to meet the evolving needs for precision diagnostics.”

By partnering with DiaCarta, AnchorDx aims to speed up its early cancer screening programmes and develop an advanced product pipeline.

AnchorDx founder and CEO Dr Jian-Bing Fan said: “We are committed to bringing the best cancer diagnostic products to the global market.

"Towards that goal, we are excited to work with the world-leading diagnostics company DiaCarta to commercialise our leading cancer screening products and co-develop future cancer screening diagnostic tests.”

In January 2023, DiaCarta obtained emergency use authorisation from the FDA for its QuantiVirus monkeypox virus (MPXV) test to qualitatively detect MPXV DNA in lesion swabs collected from people suspected of infection.